紫杉醇每周给药同步调强放射治疗食管癌的效果观察  

Paclitaxel chemotherapy and intensity modulated radiation therapy for esophageal carcinoma

作　　者：刘丽华 谢朝辉 张振才 刘金凤 王薇 刘秀春 

机构地区：[1]河北省承德市肿瘤医院,067000

出　　处：《实用医技杂志》2012年第1期7-8,共2页Journal of Practical Medical Techniques

基　　金：承德市科学技术研究与发展计划项目(201121067)

摘　　要：目的探讨紫杉醇单药同步调强放射治疗食管癌的近期疗效、局部控制率及毒性作用。方法60例食管癌患者为调强放射治疗＋紫杉醇组（放化组），43例为单纯调强放射治疗组（单放组）。调强放射治疗，95％计划靶区（PTV）：66Gv／30。33次，每周5次；放射治疗第1天即紫杉醇60mg静脉滴注，每周1次，共6次。结果病灶近期有效率放化组83％，单放组60％；1、2年生存率，单放组为56％、33％，放化组为87％、68％，差异有统计学意义（P〈0．05）。不良反应放化组稍高于单放组，但差异无统计学意义。结论紫杉醇单药每周方案同步调强放射治疗食管癌近期疗效和局部控制率较好，可能提高远期生存率，虽毒性反应增加但能耐受。Objective To evaluate the short-term efficacy, local control rates, survival rates and toxicity of con- current paclitaxel chemotherapy and intensity modulated radiation therapy （[MRT） for esophageal carcinoma. Methods One hundred and three esophageal carcinoma patients were randomized in two groups： 60 cases was treated with concurrent IMRT and paclitaxel chemotherapy （named chemo-radiation group）; another 43 cases with radiotherapy only（named radiotherapy group）. All patients were irradiation 2.0 Gy/per fraction by planning target volume （PTV） 95%, five fractions a week, the total radiation dose was 66 Gy in tumor. Besides, the chemo-radistion group was also received the concurrent chemotherapy with 60 mg of paclitaxel every week when radiation. Results The chemo-radiation group is more effective than radiotherapy group, and there was significant difference between 2 groups （P〈O.05）. 1-year, 2-year survival rates of chemo-radiation group and radiation group were 87%, 68% and 56%, 33%, respectively, and the difference is statistically significant. Conclusion Concurrent paclitaxel chemotherapy and IMRT for esophageal carcinoma can improve the short-term efficacy and local control rate, and hence improve the long-term survival rate with lightly higher and tolerable toxicity.

关 键 词：食管肿瘤 肿瘤治疗方案 放射疗法 

分 类 号：R735.1[医药卫生—肿瘤]